Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Drug Pipeline Insight Market Report 2022 Featuring Hybrigenics, MC2 Therapeutics, Lipidor/Cerbios-Pharma, OPKO Renal, & Chugai Pharmaceutical – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

“Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist – Pipeline Insight, 2022” report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist

The report assesses the active Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the Report

• Provides a snapshot of the therapeutics pipeline activity for Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist
• Features the Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages
• Offers detailed therapeutic product profiles of Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist

Key Topics Covered:

1. Report Introduction

2. Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist – Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist

4. Comparative Analysis

5. Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Pipeline Products in Clinical Stages

• Product Description
• Research and Development
• Product Development Activities

6. Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Pipeline Products in Non-clinical Stages

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment: Active Products

• Pipeline Assessment by Route of Administration
• Pipeline Assessment by Stage and Route of Administration
• Pipeline Assessment by Molecule Type
• Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

• Product Description
• Research and Development
• Product Development Activities
• Reason for dormancy/discontinuation

Companies Mentioned

• Hybrigenics
• MC2 Therapeutics
• Lipidor/Cerbios-Pharma
• OPKO Renal
• Chugai Pharmaceutical

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/tlftl6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900